O2h Ventures

Co-founder of the o2h Group and a life sciences entrepreneur who previously co-founded Oxygen Healthcare (acquired by Piramal). A UKBAA Angel Investor of the Year (2019), he serves as chair, director, or investor across 20+ UK biotech companies and holds a biochemistry degree from Keele and an MBA from Cambridge.

A medicinal chemist with over 25 years in major pharma (Sanofi-Aventis, AstraZeneca) who leads scientific evaluation of investments at o2h Ventures. He is an inventor on 55+ publications and patents and serves as CSO of Opal Oncology.

Spent 17 years in the City as an equity research analyst and fund manager, building a UK Income fund to over £1bn AUM, after six years as a technology consultant at PA. He holds a Cambridge MA in Natural Sciences and an MBA from London Business School.

A scientist and biotech entrepreneur with 15+ years in drug discovery, most recently founder and CEO of NeoPhore and previously COO of PhoreMost. He holds a bachelor's from the Harvard Extension School with expertise in cancer and metabolic disease.

Leads global operations of o2h across life-science and technology investments and oversees a new research centre in Ahmedabad. Formerly with Piramal Group, he holds a PhD from Ohio University with a Harvard Medical School post-doc and is an inventor on 30+ patents and publications.

As o2h Group's Marketing Manager, he leads brand marketing, advertising, content and digital marketing, analytics, and communications. He previously worked in digital marketing for SME tech companies and an ecommerce startup.

A biotech, pharmaceutical, and venture investment veteran with 25+ years of experience, currently CEO and co-founder of Exonate. She holds a medical degree from Birmingham University and was awarded an OBE in 2008.

Brings over 18 years of post-doctoral experience in therapeutic discovery across biotech, consultancy, and CRO settings, previously EVP of Business Development at Domainex. She holds an MSc from Nottingham, a PhD in cell biology from Cambridge, and an MBA from the Open University.

Set up FreeMedic PLC in 1993, which grew into UCL Business PLC, and was involved in numerous university licenses and spinouts including PolyMASC Pharmaceuticals and Stanmore Implants Worldwide.

Leads fundraising for the o2h human health EIS and SEIS funds, drawing on business development experience across financial services, EIS/SEIS analysis, financial media, and renewable energy financing. He holds a degree in French and European Studies from Aston University.

A cancer researcher and entrepreneur who founded Horizon Discovery in 2007, growing it into a fast-growing UK biotech that listed on the London Stock Exchange in 2014. He trained with Professor Bert Vogelstein at Johns Hopkins University.

A senior compliance professional and former regulator with 28 years of experience, including compliance leadership at Brevan Howard and an investment bank. He founded Tetractys Partners LLP, a London compliance consultancy.

A senior scientist with over 15 years across industry and academia who leads scientific due diligence at o2h Ventures, focusing on pre-clinical research evaluation. Based across India and the UK, she holds a PhD in neuroscience from the Brain Research Institute in Zurich.

A search-industry professional with nearly two decades of experience in the UK, USA, and India, formerly with Egon Zehnder, Michael Page, and BSG Team Ventures. She founded Tamarind and holds economics degrees from Delhi University and Lancaster University.

Manages investor relations at o2h Ventures, overseeing investor communications, reporting coordination, and relationship management. She previously worked at the UHBW NHS Trust and Tata Consultancy Services.

A synthetic chemistry specialist with 17+ years of R&D experience who leads technical vetting of chemical assets at o2h Ventures. Formerly a senior scientist at Piramal Discovery Solutions, he holds a PhD in organic chemistry from Kadi Sarva University.

Marketing Manager at o2h Ventures overseeing the marketing lifecycle, including content, social media, and web to drive traffic. She previously worked in finance and accounting and holds an MBA from PDEU University.

Founder and CEO of Sentinel Oncology, a medicinal chemist with 25+ years of industry experience at Pfizer, Millennium, and Astex. He is a named inventor on 50+ patents and publications on small-molecule therapeutics.

Senior Fund Operations Manager and EA to the CEO at o2h Ventures, acting as a liaison for fund matters and monitoring deal flow. She holds a business administration degree from ICFAI University.

Deal Flow Manager at o2h Ventures who supports management and expansion of the investment portfolio. He holds a master's in biotechnology and previously worked as a healthcare research analyst.

A chemist with over two decades in preclinical drug discovery who oversees o2h projects in the USA region. He earned his PhD in India, did post-doctoral work at the University of Glasgow, and worked at Alembic, Evotec, o2h, and Piramal.

An experienced biotech and pharmaceutical leader in executive and board roles, a founder with 40+ patents and publications who has secured over $6 billion in deals across oncology, CNS, and other areas.